Israeli cancer drug development company Kahr raises $46.5 million


0


Israeli cancer immunotherapy company KAHR announced today the completion of a $46.5 million funding round led by aMoon with the participation of new investors BVF Partners LP, DAFNA Capital Management LLC, Peregrine Ventures, Shavit Capital, Cancer Focus Fund, and existing investors including Flerie Invest AB, Oriella Limited (CBG, headed by Vincent Tchenguiz), Pavilion Capital, Hadasit Bio Holdings Ltd (HBL), and Mirae Asset. The Jerusalem-based company is developing new, multifunctional proteins for immune recruitment. The new capital will be used to advance the clinical development of KAHR’s flagship product candidate, DSP107. KAHR develops smart immune-recruiting drugs that activate a targeted immune response by turning cancer camouflage into beacons for the immune system to attack. The company’s lead product candidate, DSP107, is currently being tested in a Phase 1/2 multicenter, open-label, dose-escalation and expansion study to evaluate the safety, pharmacokinetics and pharmacodynamics of DSP107 as monotherapy and in combination with Roche’s PD-L1-checkpoint blocker atezolizumab (Centric) in patients. Those with advanced solid tumors. Dr. Yaron Berg, CEO of KAHR, said: “The successful funding round for this respected syndicate of investors is a testament to our advanced technology platforms and promising next-generation immunotherapy pipeline. Cancer treatment is challenging in that cancer cells are constantly changing and evolving resistance to Current treatments.Another notable obstacle is the ability of cancer cells to evade recognition and elimination by the body’s immune system.Our new and multifaceted products are specifically designed to meet these challenges by detecting cancer cells to learn about the immune system, and at At the same time, providing signals to effectively trigger targeted synergistic activation of anticancer immunity.” He added, “Our unique approach puts us at the forefront of cancer immunotherapy, and with this funding we can continue to enhance our clinical assets and accelerate our preclinical projects in clinical development across multiple cancer indications for the benefit of patients who are unresponsive or resistant to current immunotherapies,” added Dr. Berg. Gore Roscholp, partner at Amon, added, “Kahr’s multifunctional immunotherapy platform has tremendous potential to address unmet needs in immuno-oncology. We are particularly excited about KAHR’s signature first-in-class CD47x41BB targeting complex, which potentially harnesses both immune systems Innate and adaptive targeting of solid tumors and hematomas.” Related Articles Cancer Treatment Kahr Medical The Oppenheimer & Co., Inc. Inc. $18 million, and Solebury Capital acted as hiring agents for the show. Published by Globes, Israel business news – en.globes.co.il – on June 16, 2021 © Copyright Globes Publisher Itonut (1983) Ltd. 2021


Like it? Share with your friends!

0

What's Your Reaction?

hate hate
0
hate
confused confused
0
confused
fail fail
0
fail
fun fun
0
fun
geeky geeky
0
geeky
love love
0
love
lol lol
0
lol
omg omg
0
omg
win win
0
win
Mitchel

0 Comments

Your email address will not be published. Required fields are marked *